TEST:

AlphaLiquid® 100

AlphaLiquid®100 is a test that enables the detection of biomarkers which can predict the efficacy/resistance of targeted therapy for one blood test across 118 cancer-related genes. AlphaLiquid® profiling test leverages liquid biopsy samples to detect tumor cell-derived circulation tumor DNA(ctDNA) that circulates in the bloodstream. A minimally invasive simple blood draw can avoid the inconvenience of surgical biopsy and detect ctDNA from bloodstream to overcome the heterogeneity in metastatic tumors which is not available for tissue biopsy in most cases.